About this trial
Per-oral endoscopic myotomy (POEM) has emerged as the endoscopic treatment of choice for achalasia, offering comparable symptom relief with laparoscopic Heller's cardiomyotomy. The main concern with POEM is the higher incidence of post-procedure gastroesophageal reflux disease (GERD), occurring in up to 50-60% of patients. In order to reduce the risk of GERD, endoscopic fundoplication has been developed as a novel procedure mimicking surgical anterior partial fundoplication that can be performed in the same session as POEM (POEM-F). Case series of POEM-F in patients with achalasia reported encouraging outcomes of low GERD rate of \~12% at 1 year. Prospective comparative data between POEM-F and conventional POEM on post-procedure GERD is current lacking. The investigators therefore designed an international multicenter prospective randomized study to investigate the efficacy of POEM-F. The investigators postulate that POEM-F could reduce the incidence of post-procedure GERD when compared with conventional POEM.
This is an international multicenter randomized controlled trial conducted between high volume expert centers from Hong Kong SAR, China, India and United States of America. Adult patients with manometry confirmed achalasia would be randomised to undergo POEM-F or POEM. The procedure would be performed by experts with vast experience in POEM. The primary outcome is the incidence of post-procedure GERD at 1 year, defined by the updated Lyon consensus. Secondary outcomes include technical and clinical success rates, adverse events, post-POEM endoscopic and manometry findings as well as patients' symptom scores.
Sample size calculation Based on existing pilot comparative data on POEM-F and POEM, it is estimated that 84 patients would be required to demonstrate a difference in post-procedure GERD of 47.6% to 18.2%, with 80% power and false positive rate of 0.05, accounting for 10% loss to follow-up.
Purpose and potential The current study proposal could demonstrate the superiority of POEM-F over POEM in reducing post-procedural GERD. It would also demonstrate the safety and reproducibility of the technique in expert centers across the globe. It could potentially replace conventional POEM as the preferred minimally invasive endoscopic treatment for achalasia.
Eligibility criteria
Qualifiers
Adult patient (age ≥18 and ≤65 years-old) and with symptomatic achalasia type I or II.
Capability of understanding and complying with the study requirements, including filling the Eckardt Score, GERD-HRQL and RSI questionnaire and signing the informed consent form.
Treatment naïve, or
Failed prior through-the-scope balloon dilation, Savary or pneumatic dilation
Disqualifiers
Patients unable or unwilling to provide consent.
Previous esophageal or gastric surgery.
Prior achalasia treatment including Heller myotomy, POEM.
Sigmoid achalasia, or significant esophageal dilatation >6cm in lower esophagus
Trial design
Treatments tested in this trial
- POEM-F
- Conventional POEM
Treatment groups
Sponsors and collaborators
Chinese University of Hong Kong
Lead sponsor
Deenanath Mangeshkar Hospital and Research Centre
Collaborator
Johns Hopkins University
Collaborator
Northwestern University
Collaborator
Nanfang Hospital, Southern Medical University
Collaborator
Asian Institute of Gastroenterology, India
Collaborator
Post Graduate Institute of Medical Education and Research, Chandigarh
Collaborator